Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2019
Net revenue:
Total net revenue		$ 396,289	$ 382,928	$ 418,785
Cost of revenue:
Total cost of revenue	[1]	236,782	233,207	256,134
Gross profit		159,507	149,721	162,651
Operating expenses:
Research and development		52,729	49,784	56,493
Selling and marketing		42,820	47,254	55,998
General and administrative		41,723	40,144	49,577
Total operating expenses		137,272	137,182	162,068
Income from operations		22,235	12,539	583
Income (loss) on equity method investment		872	(149)
Other expense, net		(27,666)	(6,700)	(14,927)
Income (loss) before provision for income taxes		(4,559)	5,690	(14,344)
Provision for income taxes		1,752	1,863	2,086
Net income (loss)		$ (6,311)	$ 3,827	$ (16,430)
Net income (loss) per share - basic		$ (0.07)	$ 0.04	$ (0.19)
Net income (loss) per share - diluted		$ (0.07)	$ 0.04	$ (0.19)
Weighted average common shares used in computing net income (loss) per share:
Basic		92,031	89,874	87,465
Diluted		92,031	90,623	87,465
Net income (loss)		$ (6,311)	$ 3,827	$ (16,430)
Foreign currency translation adjustment		1,705	(238)	(247)
Change in defined benefit pension obligation		872	(236)	(856)
Comprehensive income (loss)		(3,734)	3,353	(17,533)
Products
Net revenue:
Total net revenue	[2]	176,647	167,302	196,665
Cost of revenue:
Total cost of revenue		102,100	95,882	116,711
Services
Net revenue:
Total net revenue	[3]	219,642	215,626	222,120
Cost of revenue:
Total cost of revenue		$ 134,682	$ 137,325	$ 139,423

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $13,310 for the year ended June 30, 2021, $13,174 for the years ended June 30, 2020 and $0 for the year ended June 30, 2019, respectively. See Note 13.

[2] Includes sales to the China joint venture, an equity method investment of $12,033 for the year ended June 30, 2021, $11,202 for the years ended June 30, 2020 and $0 for the year ended June 30, 2019, respectively. See Note 13.

[3] Includes sales to the China joint venture, an equity method investment of $12,360 for the year ended June 30, 2021, $7,851 for the years ended June 30, 2020 and $0 for the year ended June 30, 2019, respectively. See Note 13.